VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 41 filers reported holding VERONA PHARMA PLC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $678,000 | -16.1% | 161,897 | 0.0% | 0.19% | +7.8% |
| Q1 2022 | $808,000 | -25.7% | 161,897 | 0.0% | 0.18% | -8.7% |
| Q4 2021 | $1,088,000 | +22.7% | 161,897 | 0.0% | 0.20% | +122.7% |
| Q3 2021 | $887,000 | -16.2% | 161,897 | 0.0% | 0.09% | -29.6% |
| Q2 2021 | $1,059,000 | -21.7% | 161,897 | 0.0% | 0.12% | -3.1% |
| Q1 2021 | $1,353,000 | -2.9% | 161,897 | -18.7% | 0.13% | +4.9% |
| Q4 2020 | $1,394,000 | +12.2% | 199,075 | 0.0% | 0.12% | -34.9% |
| Q3 2020 | $1,242,000 | -41.9% | 199,075 | -56.4% | 0.19% | -89.4% |
| Q2 2020 | $2,138,000 | +13.6% | 456,770 | 0.0% | 1.78% | +10.8% |
| Q1 2020 | $1,882,000 | -62.6% | 456,770 | -47.8% | 1.60% | -25.6% |
| Q4 2019 | $5,031,000 | +25.8% | 875,000 | 0.0% | 2.16% | +13.7% |
| Q3 2019 | $3,999,000 | -10.4% | 875,000 | 0.0% | 1.90% | -4.2% |
| Q2 2019 | $4,463,000 | -21.5% | 875,000 | 0.0% | 1.98% | -57.0% |
| Q1 2019 | $5,688,000 | -32.6% | 875,000 | 0.0% | 4.61% | -79.2% |
| Q4 2018 | $8,444,000 | – | 875,000 | – | 22.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 4,249,918 | $69,273,663 | 7.59% |
| Aisling Capital Management LP | 1,115,352 | $18,180,238 | 7.49% |
| NEA Management Company, LLC | 5,108,563 | $91,031,474 | 7.03% |
| Octagon Capital Advisors LP | 2,369,000 | $38,614,700 | 5.93% |
| Knoll Capital Management, LLC | 200,000 | $3,260,000 | 3.38% |
| Frazier Life Sciences Management, L.P. | 3,014,349 | $49,133,889 | 3.26% |
| Perceptive Advisors | 4,007,197 | $65,317,311 | 2.18% |
| RA Capital Management | 6,317,990 | $102,983,237 | 2.03% |
| Deep Track Capital, LP | 3,187,415 | $51,954,865 | 2.00% |
| Carlyle Group Inc. | 2,457,500 | $40,008,100 | 1.74% |